How to dose extended-release carbidopa-levodopa capsules (IPX203, CREXONT®) in patients with Parkinson’s disease
IPX203 (CREXONT®) is a novel, oral, extended-release (ER) carbidopa-levodopa (CD-LD) formulation, designed to rapidly achieve LD plasma concentrations similar to immediate-release (IR) CD-LD and to maintain LD concentrations for a longer duration than other oral CD-LD products. In the pivotal phase...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Clinical Parkinsonism & Related Disorders |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590112525000611 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849240161521500160 |
|---|---|
| author | Robert A. Hauser Yasar Torres-Yaghi Stanley Fisher Ghazal Banisadr |
| author_facet | Robert A. Hauser Yasar Torres-Yaghi Stanley Fisher Ghazal Banisadr |
| author_sort | Robert A. Hauser |
| collection | DOAJ |
| description | IPX203 (CREXONT®) is a novel, oral, extended-release (ER) carbidopa-levodopa (CD-LD) formulation, designed to rapidly achieve LD plasma concentrations similar to immediate-release (IR) CD-LD and to maintain LD concentrations for a longer duration than other oral CD-LD products. In the pivotal phase 3 clinical trial, IPX203 provided superior clinical benefit with fewer doses than IR CD-LD. Since the plasma concentration profile of IPX203 is different from that of IR LD, converting patients treated with IR LD to IPX203 requires a conversion strategy. In the pivotal phase 3 trial, patients on IR CD-LD were converted to IPX203 based on the most frequent single dose of the patient’s stable dosing regimen of IR CD-LD. IPX203 was initially administered 3 times per day for most patients. Further titration was then undertaken based on clinical response, and patients were dosed 2 to 4 times per day. Of 589 patients previously treated with IR CD-LD, 506 patients completed the conversion to IPX203; the mg conversion ratio for individual doses was 2.8 at the beginning of the dose-conversion period and 2.9 after titration to clinical response, with the majority of IPX203 patients (84%) dosed 3 times per day. Objective: To provide guidance on dosing of IPX203 (CREXONT®) in clinical practice. |
| format | Article |
| id | doaj-art-7f20102c186d4176b6e072b52f777553 |
| institution | Kabale University |
| issn | 2590-1125 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Clinical Parkinsonism & Related Disorders |
| spelling | doaj-art-7f20102c186d4176b6e072b52f7775532025-08-20T04:00:43ZengElsevierClinical Parkinsonism & Related Disorders2590-11252025-01-011310035710.1016/j.prdoa.2025.100357How to dose extended-release carbidopa-levodopa capsules (IPX203, CREXONT®) in patients with Parkinson’s diseaseRobert A. Hauser0Yasar Torres-Yaghi1Stanley Fisher2Ghazal Banisadr3University of South Florida, Tampa, FL, United States; Corresponding author at: USF Parkinson’s Disease and Movement Disorders Center, Parkinson Foundation Center of Excellence, Tampa 33613, USA.MedStar Georgetown University Hospital, Washington, DC, United StatesAmneal Pharmaceuticals, LLC, 400 Crossing Boulevard, Bridgewater, NJ, United StatesAmneal Pharmaceuticals, LLC, 400 Crossing Boulevard, Bridgewater, NJ, United StatesIPX203 (CREXONT®) is a novel, oral, extended-release (ER) carbidopa-levodopa (CD-LD) formulation, designed to rapidly achieve LD plasma concentrations similar to immediate-release (IR) CD-LD and to maintain LD concentrations for a longer duration than other oral CD-LD products. In the pivotal phase 3 clinical trial, IPX203 provided superior clinical benefit with fewer doses than IR CD-LD. Since the plasma concentration profile of IPX203 is different from that of IR LD, converting patients treated with IR LD to IPX203 requires a conversion strategy. In the pivotal phase 3 trial, patients on IR CD-LD were converted to IPX203 based on the most frequent single dose of the patient’s stable dosing regimen of IR CD-LD. IPX203 was initially administered 3 times per day for most patients. Further titration was then undertaken based on clinical response, and patients were dosed 2 to 4 times per day. Of 589 patients previously treated with IR CD-LD, 506 patients completed the conversion to IPX203; the mg conversion ratio for individual doses was 2.8 at the beginning of the dose-conversion period and 2.9 after titration to clinical response, with the majority of IPX203 patients (84%) dosed 3 times per day. Objective: To provide guidance on dosing of IPX203 (CREXONT®) in clinical practice.http://www.sciencedirect.com/science/article/pii/S2590112525000611CREXONTIPX203LevodopaExtended-ReleaseParkinson’s DiseaseTreatment |
| spellingShingle | Robert A. Hauser Yasar Torres-Yaghi Stanley Fisher Ghazal Banisadr How to dose extended-release carbidopa-levodopa capsules (IPX203, CREXONT®) in patients with Parkinson’s disease Clinical Parkinsonism & Related Disorders CREXONT IPX203 Levodopa Extended-Release Parkinson’s Disease Treatment |
| title | How to dose extended-release carbidopa-levodopa capsules (IPX203, CREXONT®) in patients with Parkinson’s disease |
| title_full | How to dose extended-release carbidopa-levodopa capsules (IPX203, CREXONT®) in patients with Parkinson’s disease |
| title_fullStr | How to dose extended-release carbidopa-levodopa capsules (IPX203, CREXONT®) in patients with Parkinson’s disease |
| title_full_unstemmed | How to dose extended-release carbidopa-levodopa capsules (IPX203, CREXONT®) in patients with Parkinson’s disease |
| title_short | How to dose extended-release carbidopa-levodopa capsules (IPX203, CREXONT®) in patients with Parkinson’s disease |
| title_sort | how to dose extended release carbidopa levodopa capsules ipx203 crexont r in patients with parkinson s disease |
| topic | CREXONT IPX203 Levodopa Extended-Release Parkinson’s Disease Treatment |
| url | http://www.sciencedirect.com/science/article/pii/S2590112525000611 |
| work_keys_str_mv | AT robertahauser howtodoseextendedreleasecarbidopalevodopacapsulesipx203crexontinpatientswithparkinsonsdisease AT yasartorresyaghi howtodoseextendedreleasecarbidopalevodopacapsulesipx203crexontinpatientswithparkinsonsdisease AT stanleyfisher howtodoseextendedreleasecarbidopalevodopacapsulesipx203crexontinpatientswithparkinsonsdisease AT ghazalbanisadr howtodoseextendedreleasecarbidopalevodopacapsulesipx203crexontinpatientswithparkinsonsdisease |